WHAT IS CLAIMED:

1. A monoclonal antibody which immunospecifically binds to human PSGL-1 comprising:

(i) a variable light ("VL") chain region comprising the amino acid sequence of SEQ ID NO: 3;

(ii) a heavy chain comprising variable heavy ("VH") chain region comprising the amino acid sequence of SEQ ID NO: 4; and

(iii) a human IgG4 constant region which contains a Serine to Proline substitution at amino acid 228 of the heavy chain numbered according to the EU index.

2. A monoclonal antibody which immunospecifically binds to human PSGL-1 comprising:

(i) a light chain comprising the amino acid sequence of SEQ ID NO: 1; and

(ii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 2.

3. A monoclonal antibody which immunospecifically binds to human PSGL-1 comprising:

(i) a heavy chain consisting of SEQ ID NO: 2; and

(ii) a light chain consisting of SEQ ID NO: 1.

4. A monoclonal antibody which immunospecifically binds to human PSGL-1 and comprises a heavy chain comprising:

(i) a VH chain region comprising SEQ ID NOs: 8, 9, and 10; and

(ii) a human IgG4 heavy chain constant region containing a Serine to Proline amino acid substitution at amino acid 228 of the heavy chain numbered according to the EU index and wherein the monoclonal antibody further comprises a light chain comprising a VL chain region comprising SEQ ID NOs: 5, 6, and 7.

5. The monoclonal antibody of any one of claims 1 to 4, wherein the antibody is purified.

6. A pharmaceutical composition comprising the monoclonal antibody of any one of claims 1 to 4 and a pharmaceutically acceptable carrier.

7. The pharmaceutical composition of claim 6, wherein the monoclonal antibody is purified.

8. A kit comprising a first container containing the monoclonal antibody of any one of claims 1 to 5.

9. An injection device containing the monoclonal antibody of any one of claims 1 to 5.

10. The injection device of claim 9, wherein the injection device is a syringe.

11. Use of the monoclonal antibody of any one of claims 1 to 5 in the preparation of a medicament for treating an inflammatory disorder.

12. Use of the monoclonal antibody of any one of claims 1 to 5 in the preparation of a medicament for treating graft-versus-host disease or transplant rejection.